Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX vs mFOLFOX6 as adjuvant therapy for high‑risk stage III colon cancer
KCT0006240Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, fluorouracil, irinotecan in colon cancer, sponsored by Boryung. Started Jun 2021; status: recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracilirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on KCT0006240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006240.